Relevant conflicts of interest/financial disclosures: Dr. N. Foldvary receives research support from Glaxo Smith Kline, Inc., and Dr. W.G. Ondo is a speaker and consultant for Glaxo Smith Kline, Inc., Allergan, Ipsen, TEVA, Lundbeck, and Novartis. Other authors report no disclosures. Full financial disclosures and author roles may be found in the online version of this article.
Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome †
Article first published online: 24 JAN 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 3, pages 516–519, 15 February 2011
How to Cite
Yang, Q., Li, L., Yang, R., Shen, G.-Q., Chen, Q., Foldvary-Schaefer, N., Ondo, W. G. and Wang, Q. K. (2011), Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome . Mov. Disord., 26: 516–519. doi: 10.1002/mds.23459
- Issue published online: 31 MAR 2011
- Article first published online: 24 JAN 2011
- Manuscript Accepted: 7 SEP 2010
- Manuscript Revised: 12 AUG 2010
- Manuscript Received: 15 APR 2010
- NIH. Grant Number: P50 HL077107
- China Scholarship Council
- Hubei Natural Science Funds. Grant Number: 2008CDA047
Additional Supporting Information may be found in the online version of this article.
|MDS_23459_sm_authorroles.doc||25K||Author Roles and Disclosures|
|MDS_23459_sm_supptable.doc||42K||Supporting Table 4 Summary of sequence variants identified in the PTPRD gene (ENST00000381196)|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.